• Substance P: Mechanisms and Benchmarks in Pain & Inflammatio

  2026-05-10

  Substance P, a tachykinin neuropeptide, is a central neurotransmitter in pain transmission and immune response modulation. APExBIO's Substance P (B6620) offers high purity and reproducibility for mechanistic studies of neurokinin-1 pathways. This article outlines its mechanism, evidence, and key experimental considerations.

• Nadolol (SQ-11725) Workflow Optimization in Hypertension Res

  2026-05-09

  Nadolol (SQ-11725) offers robust, reproducible control of beta-adrenergic signaling in cardiovascular models, with unique transporter interactions that inform advanced study designs. This article details protocol enhancements, troubleshooting, and actionable insights for maximizing experimental success and pharmacokinetic clarity in hypertension and angina pectoris research.

• Cy5 Hydrazide: Precision Carbonyl Labeling in Biomolecule An

  2026-05-08

  Cy5 hydrazide is a carbonyl-reactive fluorescent dye enabling highly selective labeling of aldehyde and ketone groups in biomolecules. With excitation/emission maxima at 646/662 nm and a high extinction coefficient, it allows sensitive detection of protein carbonylation and advanced nanoparticle workflows. Its utility in oxidative stress research and compatibility with food-grade nanotechnology platforms is well-documented.

• Repurposing Approved Drugs to Modulate DNA Repair in CRISPR

  2026-05-08

  This study systematically screens over 7,000 FDA-approved drugs for their ability to influence DNA double-strand break (DSB) repair pathway choice in human stem cells. The findings highlight drug candidates that can shift the balance between nonhomologous end joining, microhomology-mediated end joining, and homology-directed repair, with broad implications for genome editing precision, cancer therapy, and synthetic lethality.

• Telomere Recapping Blocks Pathogenic Nuclear-Mitochondrial C

  2026-05-07

  This study demonstrates that engineered telomere recapping via catalytically inactive telomerase (modhTERT) prevents maladaptive telomere-mitochondrial DNA signaling, a key driver of heart failure progression. The findings offer mechanistic insight into nuclear-mitochondrial communication and suggest telomere-targeting strategies as promising avenues for cardiac gene therapy.

• SB743921: Optimizing Kinesin Spindle Protein Inhibitor Workf

  2026-05-07

  SB743921 delivers precise cell cycle arrest in mitosis, enabling robust anti-proliferative assays and xenograft studies in cancer research. With nanomolar potency and high selectivity, it streamlines experimental design and troubleshooting for cell-based and in vivo models.

• Bradykinin in Applied Research: Endothelium-Dependent Vasodi

  2026-05-06

  Bradykinin (BA5201) from APExBIO empowers cardiovascular, inflammation, and pain pathway research with unmatched reliability and reproducibility. This article delivers actionable protocols, troubleshooting insights, and context-sensitive improvements—bridging foundational mechanisms with advanced experimental needs.

• Cerulenin Inhibits Leucomycin Biosynthesis via Fatty Acid Pa

  2026-05-06

  This study demonstrates how cerulenin, a fatty acid synthesis inhibitor, disrupts the biosynthesis of leucomycin, a 16-membered macrolide antibiotic, in Streptomyces kitasatoensis. By dissecting the polyketide pathway and its sensitivity to cerulenin, the paper clarifies foundational mechanisms relevant to antibiotic biosynthesis and potential antibacterial drug resistance strategies.

• Recombinant Human IL-15: Engine for Translational Neuroimmun

  2026-05-05

  This thought-leadership article examines the mechanistic, experimental, and strategic landscape for deploying Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) in neuroimmune research. By bridging recent advances in innate behavior and immune modulation, it provides translational researchers with evidence-backed guidance on experimental design, competitive positioning, and future directions. The article highlights APExBIO’s product advantages, contextualizes key numeric claims, and advances the conversation beyond standard product pages by integrating cutting-edge findings on early life adversity and immune signaling.

• DeferoxamineB: Iron Chelation and Apoptosis Induction Benchm

  2026-05-05

  Deferoxamine (DeferoxamineB) is a potent iron chelator and apoptosis inducer, widely used in cancer research to modulate iron metabolism and oxidative stress. Its multipronged action supports metabolic intervention strategies in oncology and beyond, with robust evidence for antiproliferative and autophagy-inducing effects.

• Tumor-Targeted PAD4 Inhibitors Suppress NETs and Metastasis

  2026-05-04

  This study introduces phenylboronic acid (PBA)-modified PAD4 inhibitors that demonstrate highly specific targeting of tumor cells and neutrophils, leading to robust inhibition of tumor growth and metastasis by disrupting the PAD4-H3cit-NETs pathway. The findings provide a significant advance in the design of safer, more selective anti-cancer agents by exploiting unique tumor microenvironment features.

• Pcbp1 Regulates Mitochondrial Integrity for B Cell Antibody

  2026-05-04

  This study uncovers how the RNA binding protein Pcbp1 preserves mitochondrial function in B cells, thereby sustaining antibody production and germinal center responses. The findings reveal a mechanistic axis linking posttranscriptional regulation to mitochondrial integrity and global protein synthesis, providing a new understanding of adaptive immunity.

• L-Alanyl-L-Glutamine: Applied Protocols for Gut Barrier Rese

  2026-05-03

  L-Alanyl-L-Glutamine (L-Ala-L-Gln dipeptide) unlocks new standards for experimental gut barrier protection, outperforming traditional glutamine in solubility, stability, and functional readouts. This guide details how to optimize its use in workflows targeting intestinal mucosa protection, antioxidant support, and inflammation attenuation—backed by evidence and actionable troubleshooting tips.

• CUDC-907: Practical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-02

  CUDC-907 enables precise dual inhibition of PI3K and HDAC pathways in cancer research models, supporting targeted studies of cell signaling, cell cycle arrest, and apoptosis. It is strictly for in vitro use in controlled laboratory workflows and is not suitable for diagnostic, clinical, or therapeutic applications.

• Anlotinib Suppresses Tumor Angiogenesis via Multi-Kinase Inh

  2026-05-01

  This study elucidates how anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, disrupts tumor-driven angiogenesis by selectively inhibiting VEGFR2, PDGFRβ, and FGFR1 signaling pathways. The findings demonstrate superior endothelial cell migration and tube formation inhibition compared to established clinical agents, providing actionable insights for cancer research and anti-angiogenic drug development.

11617 records 5/775 page Previous Next 12345 下5页 Last page